Remdesivir generic drug is on sale, the price is as low as $53/bottle

c including Cipla/Hetero/Mylan from June 2020 Remdesivir generic drug was launched. This approval is a restricted emergency use approval.

Cipla stated on July 8, 2020 that the price of Cipremi, a generic drug of Redcivir, is US$53.34 (4,000 Indian rupees) per 100mg specification. It is reported that it is currently the lowest price of a generic drug of Redcivir worldwide. Cipla's goal in the Indian market is to provide 80,000 bottles of the drug within the first month. Of course, it can only be obtained through the government and hospitals as a prescription drug, and it must be injected intravenously in the hospital under the supervision of medical institutions. (Previously estimated 3000-4000 rupees per bottle, about 39-52 US dollars)

Hetero's Covifor is finally priced at 5400 Indian rupees (US$71.86) per bottle (previously expected to be 5000-6000 rupees per bottle, or about 65-78 US dollars), and Mylan's Desrem is priced at 4800 Indian rupees (63.88 US dollars) per bottle. The minimum price of Gilead Sciences' original research drug Remdesivir in developed countries is US$390 per bottle.
 

Authorized

In May 2020, Gilead has signed non-exclusive voluntary licensing agreements with five generic drug manufacturers in India and Pakistan to further expand the supply of remdesivir. The authorization allows the following companies: Cipla Ltd., Ferozsons Laboratories, Hetero Labs Ltd., Jubilant Life sciences and Mylan to produce remdesivir and supply it to 127 countries. These countries cover almost all low-income and low-middle-income countries, as well as some high-income and high-income countries (excluding China) that face significant medical barriers.

 Based on the license agreement, these companies will obtain Gilead’s technology transfer of Redcivir production process to accelerate the expansion of production scale. The authorization also sets the price of the generic drugs they produce. If the World Health Organization (World Health Organization) announces that the global new coronavirus pneumonia public health emergency is lifted, or if there are other drugs or vaccines approved for the treatment or prevention of new coronavirus pneumonia in addition to remdesivir, in any of the above Before the situation occurred, this authorization was exempt from patent fees.
 

Original research approved in many countries/regions

On July 3, 2020, Gilead announced that the European Commission has granted Veklury® (remdesivir) a conditional marketing authorization to treat viral infections that can cause new coronavirus pneumonia. The conditional marketing authorization is granted based on the rolling review of supporting data starting in April 2020, while taking into account the public health benefits in the context of the new coronavirus pneumonia pandemic.

Under this authorization, Veklury can be used to treat adults and adolescents (12 years old and above, weighing at least 40 kg) patients with new coronavirus pneumonia, and the patients have symptoms of pneumonia and require supplementary oxygen. Veklury is the first EU-approved treatment plan for new coronavirus pneumonia.

Veklury (Remdesivir) is a nucleotide analogue that has broad-spectrum antiviral activity both in vivo and in vitro, and can resist a variety of emerging viral pathogens. Multiple ongoing global phase III clinical trials are evaluating the safety and effectiveness of remdesivir in the treatment of new coronavirus pneumonia. In view of the current public health emergency and existing clinical data, Redecive has been approved in Japan, Taiwan, India, Singapore, the United Arab Emirates, the European Union, and Australia for the treatment of severe patients with novel coronavirus pneumonia. Outside these areas, Remdesivir is still an unapproved drug under development.

It is worth noting that the newly developed Remdesivir nebulized inhalation solution is in clinical practice.